Disease · MONDO_0005445

visceral leishmaniasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. visceral leishmaniasis. Diseases, record MONDO_0005445. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005445

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: visceral leishmaniasis; Open Targets
Open Targets ID: MONDO_0005445; Open Targets
Other names: VL, kala-azar, viscus leishmaniasis; Open Targets
Disease Ontology: DOID:9146; Disease Ontology
MeSH: D007898; MeSH
NCI Thesaurus: C34771; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 12 drugs, from DailyMed; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AMPHOTERICIN B	CHEMBL267345	Small molecule	Approval	DailyMed	18	17	17	Drugs and targets
MILTEFOSINE	CHEMBL125	Small molecule	Approval	DailyMed	14	12	12	Drugs and targets
PAROMOMYCIN	CHEMBL370143	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
SODIUM STIBOGLUCONATE	CHEMBL6067962	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
PAROMOMYCIN SULFATE	CHEMBL2206196	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LXE-408	CHEMBL4748352	Small molecule	Phase 2	ClinicalTrials.gov and TTD	3	2	2	Drugs and targets
FEXINIDAZOLE	CHEMBL1631694	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SITAMAQUINE	CHEMBL57004	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SCH-708980	CHEMBL2109460		Phase 1/2	ClinicalTrials.gov	1	1	0	Drugs and targets
GSK-3494245	CHEMBL5095239	Small molecule	Phase 1	TTD	1	0	0	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
IL10	Interleukin-10	1	Interleukin-10 inhibitor	Phase 1/2	https://conductscience.org/library/genes/3586

Source Drugs and targets

Trials33

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00662012	Sodium Stibogluconate Treatment of Leishmaniasis	Phase 2	414	2017-03-09	Leishmaniasis	SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT00657618	Use of Sodium Stibogluconate as a Treatment for Leishmaniasis	Phase 1/2	77	2018-02-27	Leishmaniasis	SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT00310505	Amphotericin B Treatment in Visceral Leishmaniasis	Not applicable	1,500		Visceral Leishmaniasis	AMPHOTERICIN B	Its record names the disease	ClinicalTrials.gov
NCT01566552	Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis	Phase 4	1,300		Visceral Leishmaniasis	AMPHOTERICIN B	Its record names the disease	ClinicalTrials.gov
NCT00255567	Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis	Phase 3	1,142		Visceral Leishmaniasis	PAROMOMYCIN, SODIUM STIBOGLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT00216346	Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis	Phase 3	667		Visceral Leishmaniasis	AMPHOTERICIN B, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00696969	Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis	Phase 3	634		Visceral Leishmaniasis	AMPHOTERICIN B, MILTEFOSINE, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00523965	Combination Therapy in Indian Visceral Leishmaniasis	Phase 3	624		Leishmaniasis, Visceral	AMPHOTERICIN B, MILTEFOSINE, PAROMOMYCIN SULFATE	Its record names the disease	ClinicalTrials.gov
NCT01122771	Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh	Phase 3	602		Visceral Leishmaniasis	AMPHOTERICIN B, MILTEFOSINE, PAROMOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00876824	To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar	Phase 3	500		Leishmaniasis, Visceral	AMPHOTERICIN B	Its record names the disease	ClinicalTrials.gov

1 to 10 of 33

See all 33 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30789910	RESULT	1	PubMed
30653490	RESULT	1	PubMed
21633025	RESULT	1	PubMed
21129762	RESULT	1	PubMed
36164254	DERIVED	1	PubMed
30188978	DERIVED	1	PubMed
28558062	DERIVED	1	PubMed
27627654	DERIVED	1	PubMed
27188804	DERIVED	1	PubMed
26573827	DERIVED	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005445

GET https://conductscience.org/api/diseases/v1/MONDO_0005445/trials?page=2

API reference For AI assistants